L-Norleucine

We are L-Norleucine CAS:327-57-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


L-Norleucine
CAS:327-57-1
 

Solubility in 3M-HCl	Colorless & clear (c=4)
Specific rotation [α]D20	+23.5°～+24.5°(c= 4, 6M-HCl)
Loss on drying	Not more than 0.3%
Residue on ignition (as sulfate)	Not more than 0.1%
Chloride (Cl)	Not more than 0.02%
Sulfate (SO4)	Not more than 0.03%
Heavy metals (as Pb)	Not more than 10ppm
Iron (Fe)	Not more than 10ppm
Arsenic (As2O3)	Not more than 1ppm
Other amino acids	Not detected by T.L.C.(The spotted amount, 20μg)
Assay	98.5%～101.0%

 




Related News: The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.(S)-α,α-Diphenyl-3-pyrrolidineacetamide CAS:133099-11-3 Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.4-bromo-2,6-dimetilanilina CAS:24596-19-8 Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment.2-methoxy-3-propan-2-ylpyrazine Taking Minuo Huawei as an example, in 2016, the capacity utilization rate and production-sales ratio of its multiple drug substance varieties reached more than 90%. Therefore, domestic API companies have expanded their production capacity in recent years to meet the growing demand for APIs.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.